Lantheus Holdings, Inc. Stock price

Equities

LNTH

US5165441032

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 12:20:12 2024-03-28 pm EDT 5-day change 1st Jan Change
61.96 USD +2.47% Intraday chart for Lantheus Holdings, Inc. +5.52% -0.06%
Sales 2024 * 1.43B Sales 2025 * 1.52B Capitalization 4.14B
Net income 2024 * 330M Net income 2025 * 434M EV / Sales 2024 * 2.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.72 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
10.2 x
Employees 834
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.6%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.91%
1 week+2.16%
Current month-7.53%
1 month-11.43%
3 months-1.71%
6 months-8.25%
Current year-2.48%
More quotes
1 week
57.92
Extreme 57.92
60.54
1 month
56.44
Extreme 56.44
66.81
Current year
50.20
Extreme 50.2
69.73
1 year
50.20
Extreme 50.2
100.85
3 years
19.30
Extreme 19.301
100.85
5 years
8.67
Extreme 8.67
100.85
10 years
1.76
Extreme 1.76
100.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 12-08-31
President 43 20-01-26
Director of Finance/CFO 57 18-09-20
Members of the board TitleAgeSince
Chief Executive Officer 64 12-08-31
Director/Board Member 80 18-01-31
Director/Board Member 78 12-04-30
More insiders
Date Price Change Volume
24-03-28 61.98 +2.51% 234 857
24-03-27 60.46 +2.91% 687,854
24-03-26 58.75 -0.47% 1,158,819
24-03-25 59.03 +0.02% 1,011,799
24-03-22 59.02 +0.51% 840,952

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company's products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company's license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
60.46 USD
Average target price
93.67 USD
Spread / Average Target
+54.92%
Consensus
  1. Stock
  2. Equities
  3. Stock Lantheus Holdings, Inc. - Nasdaq